Indaptus Therapeutics To Present New Positive Data On Decoy20 At Next-Gen Immuno-Oncology Conference
Portfolio Pulse from Benzinga Newsdesk
Indaptus Therapeutics (NASDAQ: INDP) will present new positive data on its lead product candidate, Decoy20, at the 7th Annual Next-Gen Immuno-Oncology Conference in Boston on June 20-21, 2024. The presentation will include preliminary results from an ongoing Phase 1 study of Decoy20 in patients with advanced solid tumors.
June 04, 2024 | 12:27 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Indaptus Therapeutics will present new positive data on Decoy20 at an upcoming conference, which could boost investor confidence and positively impact the stock price in the short term.
The announcement of new positive data on Decoy20, a key product candidate, at a major conference is likely to generate investor interest and optimism. This could lead to a short-term increase in INDP's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100